Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CFD | P00746 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482520 | 1.00 | TRPV1 (0.37) | TRPV1PTGS1PTGS2CFDALDH1A1 | |
| SCHEMBL4557461 | 0.96 | PARP1 (0.37) | TRPV1PTGS1PTGS2CFDALDH1A1 | |
| SCHEMBL4557463 | 0.96 | PARP1 (0.37) | TRPV1PTGS1PTGS2CFDALDH1A1 | |
| SCHEMBL4481839 | 0.92 | TRPV1 (0.37) | TRPV1PTGS2CFDALDH1A1KDM4E | |
| SCHEMBL4481834 | 0.92 | TRPV1 (0.37) | TRPV1PTGS2CFDALDH1A1KDM4E | |
| SCHEMBL4475908 | 0.89 | CMA1 (0.35) | ALDH1A1KDM4EHPGDHSD17B10PARP1 | |
| SCHEMBL4475899 | 0.89 | CMA1 (0.35) | ALDH1A1KDM4EHPGDHSD17B10PARP1 | |
| SCHEMBL4487165 | 0.89 | KMT2A (0.44) | CFDALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL4493333 | 0.89 | PARP1 (0.37) | TRPV1PTGS2CFDALDH1A1KDM4E | |
| SCHEMBL4493326 | 0.89 | PARP1 (0.37) | TRPV1PTGS2CFDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582651-B2 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-01 | — | — | US | disclosed |
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1535922-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | OPRD1, TRPV1, OPRM1 | TRPV1 2/4885PTGS1 369/4885PTGS2 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.